Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580, 000 patients from integrating randomized controlled trials and real-world studies. (15th September 2018)

• Record Type: Journal Article
• Authors: Wei, An-Hua; Gu, Zhi-Chun; Zhang, Chi; Ding, Yu-Feng; Liu, Dong; Li, Juan; Liu, Xiao-Yan; Lin, Hou-Wen; Pu, Jun
• Is Part Of: International journal of cardiology. Volume 267(2018)
• Page Start: 1
• Page End: 7
• Publication Date: 2018-09-15
• Subjects: Dabigatran etexilate -- Myocardial infarction -- Adverse drug event -- Meta-analysis; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2018.05.048
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: The question of whether the use of dabigatran etexilate is associated with a high risk of myocardial infarction (MI) remains unanswered owing to the lack of critical evidences. Methods: A comprehensive search of databases (Medline, Embase, Cochrane Library databases, andClinicalTrials.gov Website) was performed for RCTs that reported MI events and observational nationwide database studies that reported adjusted hazard ratio (HR) with dabigatran treatment. Summary HRs and 95% confidence intervals (95% CI) were calculated using random-effects models. Cumulative meta-analysis was conducted for evaluating the results as a continuum, and subgroup analyses were undertaken on the basis of study type, indication, controls, and dosage. Results: Finally, 24 studies including 588, 047 patients (44, 856 patients in 14 RCTs and 543, 191 patients in 10 observational database studies) met the inclusion criteria, among which 222, 352 (37.8%) patients receiving dabigatran and 365, 695 (62.2%) patients receiving placebo/other anticoagulants. In comparison to controls, no significant association was detected between the use of dabigatran and the higher risk of MI (HR: 0.97, 95% CI: 0.87–1.06; I 2 for heterogeneity: 26.3%, P = 0.089). The results were consistent across the key subgroups (indication, controls, and dosage, P interaction > 0.05 for each), with the exception of study type (RCTs or database studies, P interaction = 0.046). Cumulative meta-analysis was not suggestive of a temporal trend in the effect of dabigatran on MI. Conclusions: This meta-analysis confirms a low risk of MI in patients exposed to dabigatran, which seems to be validated when pooling over 580, 000 patients from RCTs and real-world studies. Highlights: Previous evidence of MI risk with dabigatran is derived mainly from the RE-LY trial. High-quality observational studies can provide crucial evidence especially when there are gaps in evidence from RCTs In fact, dabigatran does not increase the risk of MI.